PL3444334T3 - Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu - Google Patents

Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu

Info

Publication number
PL3444334T3
PL3444334T3 PL17782533T PL17782533T PL3444334T3 PL 3444334 T3 PL3444334 T3 PL 3444334T3 PL 17782533 T PL17782533 T PL 17782533T PL 17782533 T PL17782533 T PL 17782533T PL 3444334 T3 PL3444334 T3 PL 3444334T3
Authority
PL
Poland
Prior art keywords
specific
inducing antigen
positive lymphocytes
lymphocytes
positive
Prior art date
Application number
PL17782533T
Other languages
English (en)
Inventor
Hiroshi Kawamoto
Takuya Maeda
Kyoko Masuda
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60041838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3444334(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyoto University filed Critical Kyoto University
Publication of PL3444334T3 publication Critical patent/PL3444334T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17782533T 2016-04-15 2017-04-14 Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu PL3444334T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016082410 2016-04-15
EP17782533.8A EP3444334B9 (en) 2016-04-15 2017-04-14 Method for inducing antigen specific cd8 positive t cells
PCT/JP2017/015358 WO2017179720A1 (ja) 2016-04-15 2017-04-14 Ｃｄ８陽性ｔ細胞を誘導する方法

Publications (1)

Publication Number Publication Date
PL3444334T3 true PL3444334T3 (pl) 2022-01-10

Family

ID=60041838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17782533T PL3444334T3 (pl) 2016-04-15 2017-04-14 Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu

Country Status (11)

Country Link
US (2) US11401504B2 (pl)
EP (1) EP3444334B9 (pl)
JP (1) JP6948072B2 (pl)
AU (1) AU2017248985B2 (pl)
DK (1) DK3444334T3 (pl)
ES (1) ES2886631T3 (pl)
HU (1) HUE056387T2 (pl)
LT (1) LT3444334T (pl)
PL (1) PL3444334T3 (pl)
PT (1) PT3444334T (pl)
WO (1) WO2017179720A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
EP4053268B1 (en) 2017-01-20 2025-10-08 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
JP7479635B2 (ja) * 2018-07-13 2024-05-09 国立大学法人京都大学 γδＴ細胞の製造方法
EP3845638A4 (en) 2018-07-26 2022-05-11 Kyoto University METHOD OF PRODUCTION OF A CELL DELIVERED BY A RECEPTOR GENE OF A FOREIGN ANTIGEN
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
EP4219707A4 (en) 2020-09-24 2024-11-13 Kyoto University METHOD FOR PRODUCING AN EFFECTOR CELL WITH DESIRED SPECIFICITY
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JPWO2022145490A1 (pl) * 2021-01-04 2022-07-07
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
CA3214661A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
IL307358A (en) 2021-04-07 2023-11-01 Century Therapeutics Inc Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CA3213440A1 (en) * 2021-04-16 2022-10-20 Thyas Co. Ltd. A cell bank composed of ips cells for transfecting t cell receptor gene
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023164440A1 (en) 2022-02-22 2023-08-31 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
CN119365492A (zh) 2022-05-04 2025-01-24 世纪治疗股份有限公司 用hla-e和hla-g转基因工程化的细胞
AU2023284442A1 (en) 2022-06-08 2024-12-05 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
CN119698467A (zh) 2022-06-08 2025-03-25 世纪治疗股份有限公司 衍生自遗传工程化以具有膜结合的il12的诱导多能干细胞的免疫效应细胞及其用途
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
IL320650A (en) 2022-11-10 2025-07-01 Century Therapeutics Inc Genetically modified cells with chimeric anti-nectin 4 antigen receptors and uses thereof
JP2025074700A (ja) * 2023-10-30 2025-05-14 学校法人藤田学園 抗ｃｄ３８－ｃａｒを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
CN101356270B (zh) 2005-12-13 2014-02-12 国立大学法人京都大学 核重新编程因子
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
KR101188527B1 (ko) 2007-01-04 2012-10-05 칼 트리그베이슨 다능성 줄기세포를 증식할 수 있는 조성물 및 방법
AU2008231020B2 (en) 2007-03-23 2013-09-05 Wisconsin Alumni Research Foundation Somatic cell reprogramming
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP6151879B2 (ja) 2007-08-31 2017-06-21 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 体細胞を再プログラミングすることにおけるｗｎｔ経路の刺激
EP2096169B1 (en) 2007-10-31 2020-11-18 Kyoto University Nuclear reprogramming method
EP2242838A1 (en) 2007-12-17 2010-10-27 GliaMed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
WO2009091659A2 (en) 2008-01-16 2009-07-23 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
EP2250252A2 (en) 2008-02-11 2010-11-17 Cambridge Enterprise Limited Improved reprogramming of mammalian cells, and the cells obtained
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
US20110014164A1 (en) 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2009117439A2 (en) 2008-03-17 2009-09-24 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009114949A1 (en) 2008-03-20 2009-09-24 UNIVERSITé LAVAL Methods for deprogramming somatic cells and uses thereof
CA2718830C (en) 2008-03-31 2017-04-18 Kyoto University Method for proliferation of pluripotent stem cells
KR20110019727A (ko) 2008-04-07 2011-02-28 뉴포텐셜, 인크. Ｒｎａ 간섭을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
KR101606943B1 (ko) 2008-06-27 2016-03-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
US9453204B2 (en) 2008-07-14 2016-09-27 Oklahoma Medical Research Foundation Production of pluripotent cells through inhibition of bright/ARID3a function
DK2322611T3 (en) 2008-07-16 2016-09-05 Ip Pharma Co Ltd A process for producing reprogrammed cells using chromosomally non-integrated viral vector
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US8257897B2 (en) 2008-09-19 2012-09-04 Xerox Corporation Toners with fluorescence agent and toner sets including the toners
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
WO2010042800A1 (en) 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
WO2010050626A1 (en) 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
WO2010056831A2 (en) 2008-11-12 2010-05-20 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
WO2010068955A2 (en) 2008-12-13 2010-06-17 Dna Microarray MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING
US8951801B2 (en) 2009-02-27 2015-02-10 Kyoto University Method for making IPS cells
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
US20120076762A1 (en) 2009-03-25 2012-03-29 The Salk Institute For Biological Studies Induced pluripotent stem cell generation using two factors and p53 inactivation
US9340775B2 (en) 2009-03-25 2016-05-17 The Salk Institute For Biological Studies Induced pluripotent stem cell produced by transfecting a human neural stem cell with an episomal vector encoding the Oct4 and Nanog proteins
WO2010115050A2 (en) 2009-04-01 2010-10-07 The Regents Of The University Of California Embryonic stem cell specific micrornas promote induced pluripotency
EP2421956A4 (en) 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
JP5765714B2 (ja) 2009-05-29 2015-08-19 国立大学法人京都大学 人工多能性幹細胞の製造方法および培養方法
WO2010147395A2 (en) 2009-06-16 2010-12-23 Korea Research Institute Of Bioscience And Biotechnology Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
JP5590646B2 (ja) 2009-10-08 2014-09-17 国立大学法人大阪大学 ヒト多能性幹細胞用培養基材およびその利用
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JP2014514927A (ja) 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
WO2013176197A1 (ja) * 2012-05-22 2013-11-28 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
SG10201900323SA (en) 2014-07-18 2019-02-27 Univ Kyoto Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
PL3170896T3 (pl) 2014-07-18 2020-11-02 Kawamoto, Hiroshi Sposób wytwarzania pluripotencjalnych komórek macierzystych mających gen swoistego wobec antygenu receptora komórek T
WO2016010153A1 (ja) 2014-07-18 2016-01-21 宏 河本 免疫細胞療法用ｔ細胞の誘導方法
US10660915B2 (en) 2014-11-13 2020-05-26 Kyoto University Method for induction of T cells from pluripotent stem cells

Also Published As

Publication number Publication date
EP3444334B1 (en) 2021-08-11
US12391921B2 (en) 2025-08-19
LT3444334T (lt) 2021-12-10
EP3444334A4 (en) 2019-12-18
WO2017179720A1 (ja) 2017-10-19
EP3444334A1 (en) 2019-02-20
DK3444334T3 (da) 2021-11-08
AU2017248985B2 (en) 2023-01-12
HUE056387T2 (hu) 2022-02-28
US11401504B2 (en) 2022-08-02
PT3444334T (pt) 2021-09-08
ES2886631T9 (es) 2024-03-18
AU2017248985A1 (en) 2018-11-29
JP6948072B2 (ja) 2021-10-13
ES2886631T3 (es) 2021-12-20
EP3444334B9 (en) 2023-12-20
JPWO2017179720A1 (ja) 2019-02-28
US20190161727A1 (en) 2019-05-30
US20220251506A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
PL3444334T3 (pl) Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu
IL285403A (en) Mhc class i epitope delivering polypeptides
IL286962A (en) Selectively altering microbiota for immune modulation
IL284348A (en) Hiv pre-immunization and immunotherapy
IL264607A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
IL258692A (en) Additive manufacturing system and method
IL257071A (en) New methods for inducing an immune response
EP3405190A4 (en) METHOD FOR TRIGGERING AN IMMUNE REACTION
IL299926A (en) Neoantigens and methods of their use
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
DK3180447T3 (da) Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
DK3371619T3 (da) Detektering af et ubemandet luftfartøj
EP3485380A4 (en) CLOUD MIGRATION AND MAINTENANCE CONTROLS
PL3379690T3 (pl) Sposób i system szybkiego ładowania
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
EP3294374C0 (en) PRIMING DEVICE AND METHOD OF USE
EP4141374C0 (en) DRUM CHARGER ASSEMBLY AND METHODS
EP3310367A4 (en) INDUCTION OF LAMINA-PROPRIA-REGULATORY T-CELLS
EP3157564C0 (en) ANTIBODY ANTAGONISTS OF ALPHA AND OMEGA INTERFERONS
GB201621686D0 (en) Novel methods for inducing an immune response
EP3493872A4 (en) Microarrays and methods
IL257728B (en) Systems and methods for genetic analysis of metastases
ZA201605955B (en) Novel methods for inducing an immune response
IL250618A0 (en) Motor control system and method
DK3313431T3 (da) Fremgangsmåde til inducering af et tidligt t-hukommelsesrespons med antitumorvaccine med korte peptider